מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
EPIRUBICIN HYDROCHLORIDE
UMAN PHARMA INC
L01DB03
EPIRUBICIN
2MG
SOLUTION
EPIRUBICIN HYDROCHLORIDE 2MG
INTRAVENOUS
5ML/25ML/100ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0116901002; AHFS:
APPROVED
2009-02-04
_Epirubicin Hydrochloride Injection Product Monograph _ _Page 1 of 39 _ PRODUCT MONOGRAPH PR EPIRUBICIN HYDROCHLORIDE INJECTION 2 mg epirubicin hydrochloride/mL Sterile Professed Standard ANTINEOPLASTIC AGENT Uman Pharma Inc. Date of Preparation: January 29, 2009 100, boul. De l’industrie Date of Revision: - Candiac, QC, J5R 1J1 Canada SUBMISSION CONTROL NO.: 127398 _Epirubicin Hydrochloride Injection Product Monograph _ _Page 2 of 39 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..............................................………3 SUMMARY PRODUCT INFORMATION ........................................................………..3 INDICATIONS AND CLINICAL USE ..............................................................………..4 CONTRAINDICATIONS ..................................................................................………...4 WARNINGS AND PRECAUTIONS ...................................................................………..5 ADVERSE REACTIONS .....................................................................................………..9 DRUG INTERACTIONS ..................................................................................………..13 DOSAGE AND ADMINISTRATION ..............................................................………..13 OVERDOSAGE ................................................................................................………..16 ACTION AND CLINICAL PHARMACOLOGY ...........................................………...17 STORAGE AND STABILITY .......................................................................………......18 SPECIAL HANDLING INSTRUCTIONS ..................................................……….......19 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................………...........20 PART II: SCIENTIFIC INFORMATION...............................................................……….....22 PHARMACEUTICAL INFORMATION ....................................................………........22 CLINICAL TRIALS ........ קרא את המסמך השלם